» Articles » PMID: 37069504

Efficacy of Curcumin for Amelioration of Radiotherapy-induced Oral Mucositis: a Preliminary Randomized Controlled Clinical Trial

Overview
Journal BMC Cancer
Publisher Biomed Central
Specialty Oncology
Date 2023 Apr 18
PMID 37069504
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Oral mucositis (OM) is one of the main problems in almost all patients undergoing head and neck radiotherapy (RT). Owning to the antioxidant and anti-inflammatory properties of curcumin, the effect of both oral and topical formulations of curcumin was assessed on radiation-induced OM (ROM) in this study.

Methods: The safety and efficacy of curcumin mouthwash 0.1% (w/v) and curcumin-nanocapsule were evaluated in ameliorating severity and pain/burning associated with OM during RT. The current randomized, placebo-controlled trial was conducted on 37 patients with head and neck cancers. Patients with grades 1 to 3 of ROM were randomized to receive one of the three interventions: curcumin mouthwash (0.1% w/v); Sinacurcumin soft gel containing 40 mg curcuminoids as nano-micelles (SinaCurcumin®40); or placebo mouthwash with a similar transparent appearance to curcumin mouthwash for 1 min three times daily during RT. Study evaluations were conducted at baseline and weekly thereafter for up to 3 weeks using the Numeric rating scale (NRS) and world health organization (WHO) scale.

Results: Among the 45 patients randomized, 37 (mean (SD) age of 53.36 (15.99) years; 14 [37.8%] women) completed the treatment according to the protocol. Patients treated with either oral or topical curcumin showed a significantly reduced severity and burning related to OM during the first 3 weeks after administration (P-Value < 0.001) as compared with the placebo. At study termination, more than 33% of subjects utilizing curcumin mouthwash and 15% of patients utilizing curcumin-nanocapsule remained ulcer free while all of the placebo-receiving subjects had OM. The reduction of NRS and WHO scale between curcumin groups was comparable without significant differences.

Conclusion: Both curcumin mouthwash and nanocapsule were effective, safe, and well-tolerated in the treatment of radiation-induced OM. Higher doses of curcumin and larger sample sizes can be used for further investigation in future studies.

Trial Registration: https://irct.ir/ IRCT20190810044500N17 (13/08/2021).

Citing Articles

The Therapeutic Effects of Curcumin on Oral Disease: A Systematic Review.

Indriyani N, Nuraeny N Clin Pharmacol. 2025; 17:13-24.

PMID: 40034679 PMC: 11874755. DOI: 10.2147/CPAA.S506396.


Evaluation of Preclinical Efficacy of Curcumin-Loaded Bicosome Systems in Amelioration of Oral Mucositis.

Vergara D, Sanhueza C, Mendez S, Bustamante M, Vega B, Acevedo F Pharmaceutics. 2025; 17(2).

PMID: 40006548 PMC: 11860046. DOI: 10.3390/pharmaceutics17020181.


Network Pharmacology and Metabolomics Reveal Anti-Ferroptotic Effects of Curcumin in Acute Kidney Injury.

Liu X, Zhou Y, Lu Z, Yang F, Wang Y, Zhang S Drug Des Devel Ther. 2024; 18:6223-6241.

PMID: 39722679 PMC: 11669278. DOI: 10.2147/DDDT.S486286.


Potential Strategies for Overcoming Drug Resistance Pathways Using Propolis and Its Polyphenolic/Flavonoid Compounds in Combination with Chemotherapy and Radiotherapy.

Orsolic N, Jazvinscak Jembrek M Nutrients. 2024; 16(21).

PMID: 39519572 PMC: 11547968. DOI: 10.3390/nu16213741.


The Effectiveness of Curcumin in Treating Oral Mucositis Related to Radiation and Chemotherapy: A Systematic Review.

Dipalma G, Inchingolo A, Latini G, Ferrante L, Nardelli P, Malcangi G Antioxidants (Basel). 2024; 13(10).

PMID: 39456414 PMC: 11504953. DOI: 10.3390/antiox13101160.


References
1.
Zhang F, Subbaramaiah K, Altorki N, Dannenberg A . Dihydroxy bile acids activate the transcription of cyclooxygenase-2. J Biol Chem. 1998; 273(4):2424-8. DOI: 10.1074/jbc.273.4.2424. View

2.
Lalla R, Bowen J, Barasch A, Elting L, Epstein J, Keefe D . MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2014; 120(10):1453-61. PMC: 4164022. DOI: 10.1002/cncr.28592. View

3.
Yao Q, Ye X, Wang L, Gu J, Fu T, Wang Y . Protective effect of curcumin on chemotherapy-induced intestinal dysfunction. Int J Clin Exp Pathol. 2013; 6(11):2342-9. PMC: 3816802. View

4.
Lyons A, Crichton S, Pezier T . Trismus following radiotherapy to the head and neck is likely to have distinct genotype dependent cause. Oral Oncol. 2013; 49(9):932-936. DOI: 10.1016/j.oraloncology.2013.05.009. View

5.
Elad S, Cheng K, Lalla R, Yarom N, Hong C, Logan R . MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2020; 126(19):4423-4431. PMC: 7540329. DOI: 10.1002/cncr.33100. View